跳转至内容
Merck

890890P

Avanti

18:1 TAP (DOTAP)

Avanti Research - A Croda Brand

别名:

1,2-二油酰基-3-三甲基铵-丙烷 (氯盐), DOTAP

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C42H80NO4Cl
分子量:
698.54
分類程式碼代碼:
12352211
NACRES:
NA.25

形狀

powder

包裝

pkg of 1 × 1 g ((890890P-1G))
pkg of 2 × 100 mg ((890890P-200MG))
pkg of 5 × 100 mg ((890890P-100MG))
pkg of 1 × 25 mg ((890890P-25MG))

製造商/商標名

Avanti Research - A Croda Brand

應用

advanced drug delivery

脂質類型

transfection
cationic lipids

運輸包裝

dry ice

儲存溫度

−20°C

SMILES 字串

[H]C(C[N+](C)(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O.[Cl-]

InChI

1S/C42H80NO4.ClH/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-41(44)46-39-40(38-43(3,4)5)47-42(45)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;/h20-23,40H,6-19,24-39H2,1-5H3;1H/q+1;/p-1/b22-20-,23-21-;

InChI 密鑰

KSXTUUUQYQYKCR-LQDDAWAPSA-M

應用

18:1 TAP (DOTAP)可用于在氯仿溶液中形成干膜,制备阳离子脂质体。也用于标准储备溶液中,制备阳离子脂质体。

生化/生理作用

DOTAP(1,2-二油酰基-3-三甲基铵-丙烷)为阳离子脂质结构,用于体内体外核酸和蛋白递送。脂质组成和细胞类型会影响 DOTAP 的转染潜能。DOTAP介导造血干细胞(HSCs)的基因敲低技术。

包裝

5 mL透明玻璃密封安瓿瓶(890890P-200mg)
5 mL透明玻璃密封安瓿瓶(890890P-25mg)
5 mL透明玻璃密封安瓿瓶(890890P-500mg)
60 mL琥珀色宽口螺帽玻璃瓶(890890P-1g)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

也與該產品經常一起購買

产品编号
说明
价格

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Cationic liposomes induce cytotoxicity in HepG2 via regulation of lipid metabolism based on whole-transcriptome sequencing analysis
Li Y, et al.
BMC Pharmacology & Toxicology, 19(1), 43-43 (2018)
Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells
Martino S, et al.
BioMed Research International, 2009 (2009)
Analysis of cationic liposomes by reversed-phase HPLC with evaporative light-scattering detection
Zhong Z, et al.
Journal of Pharmaceutical and Biomedical Analysis, 51(4), 947-951 (2010)
DOTAP (and other cationic lipids): chemistry, biophysics, and transfection
Simberg D, et al.
Critical Reviews in Therapeutic Drug Carrier Systems, 21(4) (2004)
Elias J Sayour et al.
Nano letters, 18(10), 6195-6206 (2018-09-28)
Translation of nanoparticles (NPs) into human clinical trials for patients with refractory cancers has lagged due to unknown biologic reactivities of novel NP designs. To overcome these limitations, simple well-characterized mRNA lipid-NPs have been developed as cancer immunotherapeutic vaccines. While

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门